FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 335:751-752 September 5, 1996 Number 10 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Schreiber, S. PubMed Citation

To the Editor: In their study of recombinant erythropoietin for the treatment of anemia in inflammatory bowel disease (March 7 issue),¹ Schreiber et al. found that treatment with oral iron and recombinant erythropoietin can raise hemoglobin levels. Usually, chronic anemia with hemoglobin levels between 7 and 8 g per deciliter is well tolerated by younger patients, because of a variety of compensatory mechanisms. In view of the only moderately decreased hemoglobin levels at the beginning of the trial (mean hemoglobin level in the placebo group, 8.69 g per deciliter; in the treatment group, 8.81 g per deciliter) and the young . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.